The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation

Autor: França,P.H.C., Coelho,H.S.M., Brandão,C.E., Segadas,J.A., Quintaes,R.F., Carrilho,F.J., Ono-Nita,S., Mattos,A.A., Tovo,C., Gouvea,V.S., Sablon,E., Vanderborght,B.O.M.

Publikováno v: Brazilian Journal of Medical and Biological Research, Volume: 40, Issue: 12, Pages: 1605-1614, Published: 29 OCT 2007
Brazilian Journal of Medical and Biological Research, Vol 40, Iss 12, Pp 1605-1614 (2007)
Brazilian Journal of Medical and Biological Research v.40 n.12 2007
Brazilian Journal of Medical and Biological Research
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC

Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ffe29e29a65081324e7fa971841bea1a
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003&lng=en&tlng=en